Research ExplorerScientific StaffKatja Weisel Publications

Prof.Dr.med. ID: 6488383

Katja Weisel

graph of relations
Affiliations
151 - 200 out of 260Page size: 50
Sort by: Title

Publications

  1. Intravascular lymphoma - a rare cause of hemolytic anemia and neurologic disorders

    Weisel, K. C., Brugger, W., Kröber, S. M., Kaiserling, E. & Kanz, L., 2004, In: HEMATOL J. 5, 5, p. 444-6 3 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  2. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

    Leypoldt, L. B., Tichy, D., Besemer, B., Hänel, M., Raab, M. S., Mann, C., Munder, M., Reinhardt, H. C., Nogai, A., Görner, M., Ko, Y-D., de Wit, M., Salwender, H., Scheid, C., Graeven, U., Peceny, R., Staib, P., Dieing, A., Einsele, H., Jauch, A., Hundemer, M., Zago, M., Požek, E., Benner, A., Bokemeyer, C., Goldschmidt, H. & Weisel, K. C., 01.01.2024, In: J CLIN ONCOL. 42, 1, p. 26-37 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  3. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial

    Leypoldt, L. B., Besemer, B., Asemissen, A. M., Hänel, M., Blau, I. W., Görner, M., Ko, Y-D., Reinhardt, H. C., Staib, P., Mann, C., Lutz, R., Munder, M., Graeven, U., Peceny, R., Salwender, H., Jauch, A., Zago, M., Benner, A., Tichy, D., Bokemeyer, C., Goldschmidt, H. & Weisel, K. C., 03.2022, In: LEUKEMIA. 36, 3, p. 885-888 4 p.

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  4. Ixazomib-lenalidomide-dexamethasone in routine clinical practice:effectiveness in relapsed/refractory multiple myeloma

    Hájek, R., Minařík, J., Straub, J., Pour, L., Jungova, A., Berdeja, J. G., Boccadoro, M., Brozova, L., Spencer, A., Rhee, F. V., Vela-Ojeda, J., Thompson, M. A., Abonour, R., Chari, A., Cook, G., Costello, C. L., Davies, F. E., Hungria, V. T., Lee, H. C., Leleu, X., Puig, N., Rifkin, R. M., Terpos, E., Usmani, S. Z., Weisel, K. C., Zonder, J. A., Bařinová, M., Kuhn, M., Šilar, J., Čápková, L., Galvez, K., Lu, J., Elliott, J., Stull, D. M., Ren, K. & Maisnar, V., 07.2021, In: FUTURE ONCOL. 17, 19, p. 2499-2512 14 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  5. Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma

    Ludwig, H., Poenisch, W., Knop, S., Egle, A., Schreder, M., Lechner, D., Hajek, R., Gunsilius, E., Krenosz, K. J., Petzer, A., Weisel, K., Niederwieser, D., Einsele, H., Willenbacher, W., Melchardt, T., Greil, R. & Zojer, N., 10.2019, In: BRIT J CANCER. 121, 9, p. 751-757 7 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  6. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

    Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., Banos, A., Tiab, M., Delforge, M., Cavenagh, J., Geraldes, C., Lee, J-J., Chen, C., Oriol, A., de la Rubia, J., Qiu, L., White, D. J., Binder, D., Anderson, K., Fermand, J-P., Moreau, P., Attal, M., Knight, R., Chen, G., Van Oostendorp, J., Jacques, C., Ervin-Haynes, A., Avet-Loiseau, H., Hulin, C., Facon, T. & FIRST Trial Team, 04.09.2014, In: NEW ENGL J MED. 371, 10, p. 906-17 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  7. Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment

    Zago, M., Oehrlein, K., Rendl, C., Hahn-Ast, C., Kanz, L. & Weisel, K., 12.2014, In: ANN HEMATOL. 93, 12, p. 1993-9 7 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  8. Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

    Baertsch, M-A., Mai, E. K., Hielscher, T., Bertsch, U., Salwender, H. J., Munder, M., Fuhrmann, S., Dührsen, U., Brossart, P., Neben, K., Schlenzka, J., Kunz, C., Raab, M. S., Hillengaß, J., Jauch, A., Seckinger, A., Hose, D., Luntz, S., Sonneveld, P., Lokhorst, H., Martin, H., Goerner, M., Hoffmann, M., Lindemann, H-W., Bernhard, H., Blau, I. W., Scheid, C., Besemer, B., Weisel, K. C., Hänel, M., Dürig, J., Goldschmidt, H. & German-speaking Myeloma Multicenter Group (GMMG), 07.01.2021, In: BLOOD CANCER J. 11, 1, p. 1

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  9. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

    Mateos, M-V., Weisel, K., De Stefano, V., Goldschmidt, H., Delforge, M., Mohty, M., Cavo, M., Vij, R., Lindsey-Hill, J., Dytfeld, D., Angelucci, E., Perrot, A., Benjamin, R., van de Donk, N. W. C. J., Ocio, E. M., Scheid, C., Gay, F., Roeloffzen, W., Rodriguez-Otero, P., Broijl, A., Potamianou, A., Sakabedoyan, C., Semerjian, M., Keim, S., Strulev, V., Schecter, J. M., Vogel, M., Wapenaar, R., Nesheiwat, T., San-Miguel, J., Sonneveld, P., Einsele, H. & Moreau, P., 05.2022, In: LEUKEMIA. 36, 5, p. 1371-1376 6 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  10. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study

    Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A-O., Callander, N., Sborov, D., Suvannasankha, A., Weisel, K., Voorhees, P. M., Womersley, L., Baron, J., Piontek, T., Lewis, E., Opalinska, J., Gupta, I. & Cohen, A. D., 15.11.2021, In: CANCER-AM CANCER SOC. 127, 22, p. 4198-4212 15 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  11. Longitudinal fluorescence hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation

    Merz, M., Jauch, A., Hielscher, T., Mai, E. K., Seckinger, A., Hose, D., Bertsch, U., Neben, K., Raab, M. S., Salwender, H., Blau, I. W., Lindemann, H-W., Schmidt-Wolf, I., Scheid, C., Haenel, M., Weisel, K., Goldschmidt, H. & Hillengass, J., 08.2017, In: HAEMATOLOGICA. 102, 8, p. 1432-1438 7 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  12. Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

    Salwender, H., Elmaagacli, A., Merz, M., Miah, K., Benner, A., Haenel, M., Jehn, C., Mai, E. K., Bertsch, U., Blau, I. W., Scheid, C., Hose, D., Seckinger, A., Jauch, A., Raab, M. S., Luntz, S. P., Besemer, B., Munder, M., Brossart, P., Fuhrmann, S., Lindemann, H-W., Weisel, K., Duerig, J. & Goldschmidt, H., 10.2021, In: LEUKEMIA. 35, 10, p. 3007-3011 5 p.

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  13. Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma

    Ghandili, S., Schönlein, M., Wiessner, C., Becher, H., Lütgehetmann, M., Brehm, T. T., Wiesch, J. S. Z., Bokemeyer, C., Sinn, M., Weisel, K. C. & Leypoldt, L., 24.11.2021, In: J CLIN MED. 10, 23, 5499.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  14. Maintenance and continuous therapy for multiple myeloma

    Richardson, P. G., Laubach, J., Gandolfi, S., Facon, T., Weisel, K. & O'Gorman, P., 08.2018, In: EXPERT REV ANTICANC. 18, 8, p. 751-764 14 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  15. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

    Dimopoulos, M. A., Merlini, G., Bridoux, F., Leung, N., Mikhael, J., Harrison, S. J., Kastritis, E., Garderet, L., Gozzetti, A., van de Donk, N. W. C. J., Weisel, K. C., Badros, A. Z., Beksac, M., Hillengass, J., Mohty, M., Ho, P. J., Ntanasis-Stathopoulos, I., Mateos, M-V., Richardson, P., Blade, J., Moreau, P., San-Miguel, J., Munshi, N., Rajkumar, S. V., Durie, B. G. M., Ludwig, H., Terpos, E. & International Myeloma Working Group, 07.2023, In: LANCET ONCOL. 24, 7, p. e293-e311

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  16. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life

    Terpos, E., Mikhael, J., Hajek, R., Chari, A., Zweegman, S., Lee, H. C., Mateos, M-V., Larocca, A., Ramasamy, K., Kaiser, M., Cook, G., Weisel, K. C., Costello, C. L., Elliott, J., Palumbo, A. & Usmani, S. Z., 18.02.2021, In: BLOOD CANCER J. 11, 2, p. 40

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  17. Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma

    Bilich, T., Nelde, A., Bauer, J., Walz, S., Roerden, M., Salih, H. R., Weisel, K., Besemer, B., Marcu, A., Lübke, M., Schuhmacher, J., Neidert, M. C., Rammensee, H-G., Stevanović, S. & Walz, J. S., 28.02.2020, In: BLOOD CANCER J. 10, 2, p. 24

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  18. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma

    Rodriguez-Otero, P., Ayers, D., Cope, S., Davies, F. E., Delforge, M., Mojebi, A., Jansen, J. P., Weisel, K., Hege, K. & Dhanasiri, S., 10.2021, In: LEUKEMIA LYMPHOMA. 62, 10, p. 2482-2491 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  19. Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

    Weisel, K., Krishnan, A., Schecter, J. M., Vogel, M., Jackson, C. C., Deraedt, W., Yeh, T-M., Banerjee, A., Yalniz, F., Nesheiwat, T., Van Sanden, S., Diels, J., Valluri, S., Usmani, S. Z., Berdeja, J. G., Jagannath, S. & Martin, T., 09.2022, In: CL LYMPH MYELOM LEUK. 22, 9, p. 690-701 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  20. MCT1 is a Predictive Marker for Lenalidomide Maintenance Therapy in Multiple Myeloma

    Stroh, J., Seckinger, A., Heider, M., Rudelius, M., Eichner, R., Schick, M., Slawska, J., Emde, M., Salwender, H., Bertsch, U., Goldschmidt, H., Weisel, K. C., Scheid, C., Keller, U., Hose, D. & Bassermann, F., 25.01.2022, In: BLOOD ADV. 6, 2, p. 515-520 6 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  21. Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study

    Ramasamy, K., Avet-Loiseau, H., Hveding Blimark, C., Delforge, M., Gay, F., Manier, S., Martinez-Lopez, J., Mateos, M. V., Mohty, M., van de Donk, N. W. C. J. & Weisel, K., 09.2023, In: HEMASPHERE. 7, 9, p. e942

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  22. Meeting summary: International Symposium and Workshop on Hematopoietic Stem Cells VI, University of Tübingen, Germany, September 14-16, 2006

    Weisel, K. C., Fibbe, W. E. & Kanz, L., 07.2007, In: Experimental hematology. 35, 7, p. 1005-14 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research

  23. Meeting summary: International Symposium and Workshop on Hematopoietic Stem Cells V, University of Tübingen, Germany, September 16-18, 2004

    Weisel, K. C., Brümmendorf, T. H., Orlic, D., Fibbe, W. E. & Kanz, L., 05.2005, In: Experimental hematology. 33, 5, p. 513-22 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research

  24. Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma

    Costa, L. J., Hari, P., Berdeja, J. G., De Stefano, V., Gay, F., Hooper, B., Bartlett, M., Haltner, A., Rosta, E., Kumar, S., Martin, T., Mateos, M-V., Moreau, P., Usmani, S. Z., Olyslager, Y., Schecter, J. M., Roccia, T., Garrett, A., Lee, S., Nesheiwat, T., Pacaud, L., Zhou, C., Samjoo, I. A., Lin, Y., Diels, J., Valluri, S. & Weisel, K., 10.2022, In: CURR MED RES OPIN. 38, 10, p. 1759-1767 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  25. MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1-3 Prior Lines of Therapy (LOT)

    Hillengass, J., Cohen, A. D., Delforge, M., Einsele, H., Goldschmidt, H., Weisel, K., Raab, M-S., Scheid, C., Schecter, J. M., de Braganca, K. C., Varsos, H., Yeh, T-M., Mistry, P., Roccia, T., Corsale, C., Akram, M., Pacaud, L., Nesheiwat, T., Agha, M. & Cohen, Y. C., 01.10.2022, In: CL LYMPH MYELOM LEUK. 22, Suppl 2, S411.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  26. Modern imaging techniques during therapy in patients with multiple myeloma

    Horger, M., Weisel, K., Bares, R., Ernemann, U., Claussen, C. D., Lichy, M. & Fenchel, M., 01.10.2011, In: ACTA RADIOL. 52, 8, p. 881-8 8 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  27. Modulation of CXC chemokine receptor expression and function in human neutrophils during aging in vitro suggests a role in their clearance from circulation

    Weisel, K. C., Bautz, F., Seitz, G., Yildirim, S., Kanz, L. & Möhle, R., 2009, In: MEDIAT INFLAMM. 2009, p. 790174

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  28. Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries

    Seckinger, A., Salwender, H., Martin, H., Scheid, C., Hielscher, T., Bertsch, U., Hummel, M., Jauch, A., Knauf, W., Emde-Rajaratnam, M., Beck, S., Neben, K., Dührig, J., Lindemann, W., Schmidt-Wolf, I. G. H., Hänel, M., Blau, I. W., Weisel, K., Weinhold, N., Raab, M. S., Goldschmidt, H., Choon-Quinones, M. & Hose, D., 11.06.2024, In: INT J MOL SCI. 25, 12, 6431.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  29. Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma

    Radocha, J., van de Donk, N. W. C. J. & Weisel, K., 29.03.2021, In: CANCERS. 13, 7, p. 1551

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  30. Monoklonale Gammopathie unklarer Signifikanz – ein häufiger Nebenbefund: Woran ist zu denken? Was ist zu tun?

    Schieferdecker, A., Binder, M., Weisel, K. & Bokemeyer, C., 07.2019, In: DEUT MED WOCHENSCHR. 144, 14, p. 982-989 8 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  31. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial

    Raab, M. S., Engelhardt, M., Blank, A., Goldschmidt, H., Agis, H., Blau, I. W., Einsele, H., Ferstl, B., Schub, N., Röllig, C., Weisel, K., Winderlich, M., Griese, J., Härtle, S., Weirather, J., Jarutat, T., Peschel, C. & Chatterjee, M., 05.2020, In: LANCET HAEMATOL. 7, 5, p. e381-e394

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  32. Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies

    Rees, M. J., D'Agostino, M., Leypoldt, L. B., Kumar, S., Weisel, K. C. & Gay, F., 06.2024, In: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 44, 3, p. e433520

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  33. Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study

    Ludwig, H., Weisel, K., Petrucci, M. T., Leleu, X., Cafro, A. M., Garderet, L., Leitgeb, C., Foa, R., Greil, R., Yakoub-Agha, I., Zboralski, D., Vauléon, S., Dümmler, T., Beyer, D., Kruschinski, A., Riecke, K., Baumann, M. & Engelhardt, M., 04.2017, In: LEUKEMIA. 31, 4, p. 997-1000 4 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  34. Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis

    Dimopoulos, M. A., Niesvizky, R., Weisel, K., Siegel, D. S., Hajek, R., Mateos, M-V., Cavo, M., Huang, M., Zahlten-Kumeli, A. & Moreau, P., 09.03.2020, In: BLOOD CANCER J. 10, 3, p. 35

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  35. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study

    Moreau, P., Mateos, M-V., Berenson, J. R., Weisel, K., Lazzaro, A., Song, K., Dimopoulos, M. A., Huang, M., Zahlten-Kumeli, A. & Stewart, A. K., 07.2018, In: LANCET ONCOL. 19, 7, p. 953-964 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  36. OP9 stroma augments survival of hematopoietic precursors and progenitors during hematopoietic differentiation from human embryonic stem cells

    Ji, J., Vijayaragavan, K., Bosse, M., Menendez, P., Weisel, K. & Bhatia, M., 10.2008, In: Stem cells (Dayton, Ohio). 26, 10, p. 2485-95 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  37. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

    Dimopoulos, M. A., Gay, F., Schjesvold, F., Beksac, M., Hajek, R., Weisel, K. C., Goldschmidt, H., Maisnar, V., Moreau, P., Min, C. K., Pluta, A., Chng, W-J., Kaiser, M., Zweegman, S., Mateos, M-V., Spencer, A., Iida, S., Morgan, G., Suryanarayan, K., Teng, Z., Skacel, T., Palumbo, A., Dash, A. B., Gupta, N., Labotka, R., Rajkumar, S. V. & TOURMALINE-MM3 study group, 19.01.2019, In: LANCET. 393, 10168, p. 253-264 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  38. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma

    Chari, A., Vogl, D. T., Gavriatopoulou, M., Nooka, A. K., Yee, A. J., Huff, C. A., Moreau, P., Dingli, D., Cole, C., Lonial, S., Dimopoulos, M., Stewart, A. K., Richter, J., Vij, R., Tuchman, S., Raab, M. S., Weisel, K. C., Delforge, M., Cornell, R. F., Kaminetzky, D., Hoffman, J. E., Costa, L. J., Parker, T. L., Levy, M., Schreder, M., Meuleman, N., Frenzel, L., Mohty, M., Choquet, S., Schiller, G., Comenzo, R. L., Engelhardt, M., Illmer, T., Vlummens, P., Doyen, C., Facon, T., Karlin, L., Perrot, A., Podar, K., Kauffman, M. G., Shacham, S., Li, L., Tang, S., Picklesimer, C., Saint-Martin, J-R., Crochiere, M., Chang, H., Parekh, S., Landesman, Y., Shah, J., Richardson, P. G. & Jagannath, S., 22.08.2019, In: NEW ENGL J MED. 381, 8, p. 727-738 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  39. Osteoprotegerin positively regulates hematopoietic progenitor cells

    Schweikle, E., Baessler, T., Yildirim, S., Kanz, L., Möhle, R. & Weisel, K. C., 01.2012, In: CURR STEM CELL RES T. 7, 1, p. 72-7 6 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  40. Outcome of a Real-World Patient Cohort with Secondary CNS Lymphoma Treated with High-Intensity Chemoimmunotherapy and Autologous Stem Cell Transplantation

    Thiele, B., Binder, M., Schliffke, S., Frenzel, C., Dierlamm, J., Wass, M., Weisel, K. C., Bokemeyer, C. & Janjetovic, S., 21.07.2021, In: ONCOL RES TREAT. 44, 7-8, p. 375-381 7 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  41. Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients

    Avivi, I., Vesole, D. H., Davila-Valls, J., Usnarska-Zubkiewicz, L., Olszewska-Szopa, M., Milunovic, V., Baumert, B., Osękowska, B., Kopińska, A., Gentile, M., Puertas-Martinez, B., Robak, P., Crusoe, E., Rodriguez-Lobato, L. G., Gajewska, M., Varga, G., Delforge, M., Cohen, Y., Gozzetti, A., Pena, C., Shustik, C., Mikala, G., Zalac, K., Alexander, H. D., Barth, P., Weisel, K., Martínez-López, J., Waszczuk-Gajda, A., Krzystański, M. & Jurczyszyn, A., 01.09.2023, In: CANCERS. 15, 17, 4359.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  42. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone

    Morgan, G., Palumbo, A., Dhanasiri, S., Lee, D., Weisel, K., Facon, T., Delforge, M., Oriol, A., Zaki, M., Yu, X., Sternas, L., Jacques, C., Akehurst, R., Offner, F. & Dimopoulos, M. A., 03.2015, In: BRIT J HAEMATOL. 168, 6, p. 820-3 4 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  43. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

    Sonneveld, P., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M-V., Mark, T. M., Levin, M-D., Ahmadi, T., Qin, X., Garvin Mayo, W., Gai, X., Carey, J., Carson, R. & Spencer, A., 10.03.2023, In: J CLIN ONCOL. 41, 8, p. 1600-1609 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  44. Paraneoplastic granulocyte colony-stimulating factor secretion in soft tissue sarcoma mimicking myeloproliferative neoplasia: a case report

    Dorn, C., Bugl, S., Malenke, E., Müller, M. R., Weisel, K. C., Vogel, U., Horger, M., Kanz, L. & Kopp, H-G., 23.05.2014, In: BMC RES NOTES. 7, p. 313

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  45. Pathologic fractures in patients with multiple myeloma undergoing bisphosphonate therapy: incidence and correlation with course of disease

    Vogel, M. N., Weisel, K., Maksimovic, O., Peters, S., Brodoefel, H., Claussen, C. D. & Horger, M. S., 09.2009, In: AM J ROENTGENOL. 193, 3, p. 656-61 6 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  46. Patients With Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance

    Piechotta, V., Skoetz, N., Engelhardt, M., Einsele, H., Goldschmidt, H., Scheid, C. & guideline group, 08.04.2022, In: DTSCH ARZTEBL INT. 119, 14, p. 253-260 8 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  47. Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial

    Merz, M., Salwender, H., Haenel, M., Mai, E. K., Bertsch, U., Kunz, C., Hielscher, T., Blau, I. W., Scheid, C., Hose, D., Seckinger, A., Jauch, A., Hillengass, J., Raab, M. S., Schurich, B., Munder, M., Brossart, P., Gerecke, C., Lindemann, H-W., Zeis, M., Weisel, K., Duerig, J. & Goldschmidt, H., 12.2016, In: HAEMATOLOGICA. 101, 12, p. e485-e487

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  48. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

    Davies, F. E., Pawlyn, C., Usmani, S. Z., San-Miguel, J. F., Einsele, H., Boyle, E. M., Corre, J., Auclair, D., Cho, H. J., Lonial, S., Sonneveld, P., Stewart, A. K., Bergsagel, P. L., Kaiser, M. F., Weisel, K., Keats, J. J., Mikhael, J. R., Morgan, K. E., Ghobrial, I. M., Orlowski, R. Z., Landgren, C. O., Gay, F., Caers, J., Chng, W. J., Chari, A., Walker, B. A., Kumar, S. K., Costa, L. J., Anderson, K. C. & Morgan, G. J., 06.07.2022, In: BLOOD CANCER DISCOV. 3, 4, p. 273-284 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  49. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

    Mai, E. K., Bertsch, U., Dürig, J., Kunz, C., Haenel, M., Blau, I. W., Munder, M., Jauch, A., Schurich, B., Hielscher, T., Merz, M., Huegle-Doerr, B., Seckinger, A., Hose, D., Hillengass, J., Raab, M. S., Neben, K., Lindemann, H-W., Zeis, M., Gerecke, C., Schmidt-Wolf, I. G. H., Weisel, K., Scheid, C., Salwender, H. & Goldschmidt, H., 08.2015, In: LEUKEMIA. 29, 8, p. 1721-9 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  50. Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma

    Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., Perrot, A., Weisel, K., Raje, N., Macro, M., Frenzel, L., Leleu, X., Wang, J., Rampelbergh, R. V., Uhlar, C. M., Vermeulen, J., Duran, J., Borgsten, F. & Usmani, S. Z., 04.2023, In: FUTURE ONCOL. 19, 13, p. 887-895 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Previous 1 2 3 4 5 6 Next